Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals & M&A

Set Alert for Deals & M&A

Seagen, Astellas Data Support Broader Indication For Padcev/Keytruda Combo

With accelerated approval in advanced urothelial cancer, the sponsors now have data that could support full approval plus a move into first-line therapy.

Clinical Trials Business Strategies

Deal Watch: Merck KGAA Teams With AI Biotechs On Drug Discovery Efforts

Plus deals involving Debiopharm/SunRock, RefleXion/3B Pharmaceuticals, Pharmanovia/Sanofi and more.

Deal Watch Business Strategies

Glenmark Divests API Company, Setting Out On Distinct Journeys

Glenmark Pharmaceuticals has divested its API arm to the Nirma group for over $681m, a move that will deleverage the drug maker’s balance sheet as it seeks to evolve into an “innovative/brand led organization.”

Commercial M & A

Genentech Joins Hunt For ‘Molecular Glue’ Drugs With Orionis

Genentech is broadening its stake in the protein degradation field, following BMS and Merck & Co into molecular glue drugs.

Commercial Companies

Novartis Drops BeiGene PD-1 Asset Tevimbra As Drug Wins Esophageal Cancer Nod In Europe

The Swiss drug maker’s decision to give back rights to tislelizumab means BeiGene goes without the potentially $1.55bn in milestone payments the companies had agreed to in early 2021.

ImmunoOncology Deals

Sun Backs India-First Stroke Drug From Pharmazz

Sun debuts Pharmazz Inc’s new stroke drug sovateltide in India at under $20/ vial.  The selective endothelin-B receptor agonist, which can be administered up to 24 hours post cerebral ischemic stroke, is also being studied in Alzheimer’s disease.

Commercial India

BMS Revs R&D Engine To Advance 10 New Drug Candidates Annually

Bristol aims to bring more drugs into the clinic as fast as possible without compromising on quality, with many novel molecules emerging from its productive protein degradation and cell therapy platforms.

Growth Innovation

Deal Watch: Moderna, Immactics Team Up To Combine mRNA Technology With Cancer Cell Therapy

Plus deals involving Kelun Biotech, Pierre Fabre/Vertical, Novo Nordisk/Broad Institute, ABL Bio/Synaffix, Kriya/Tramontane, Palisade/Giiant and more.

Deal Watch Business Strategies

First Wave Rises With Sanofi GI Deal

First Wave is licensing Sanofi’s 5-HT4 receptor partial agonist capeserod and is having to pay a mere $500,000 in upfront fees for the privilege.

Deals Gastrointestinal

AbbVie Bails On Harpoon’s Multiple Myeloma Drug Amid Highly Competitive Environment

Harpoon said it plans to complete the Phase I study of its anti-BCMA immuno-oncology agent HPN217 and use the data to support the next phase of development for the drug.

ImmunoOncology Deals

Pharma Cash Keeps Flowing Into Ireland

MSD and Astellas have joined Lilly, Takeda and AstraZeneca in making major investments in Ireland this year.

Ireland Deals

Hengrui, BeyondSpring In Arbitration Face-Off After Cancer Deal Setbacks

A Chinese court decision sheds light on how Chinese major Hengrui Medicine is seeking to reduce or avoid potential losses worth up to $27m following regulatory setbacks with the tubulin inhibitor plinabulin, in-licensed from BeyondSpring in 2021.

China Deals
UsernamePublicRestriction

Register